Impact of Neoadjuvant Chemotherapy on Immediate Breast Reconstruction: A Meta-Analysis

Junlong Song¹, Xiang Zhang¹, Qiang Liu², Jianheng Peng¹, Xinjie Liang¹, Yuanyuan Shen¹, Hongtao Liu¹, Hongyuan Li¹*

¹ Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China, ²Department of General Surgery, The People’s Hospital of Dazu County, Chongqing, China

Abstract

Objective: The objective of this study was to perform a meta-analysis of published studies for evaluating the impact of neoadjuvant chemotherapy (NAC) on immediate breast reconstruction.

Methods: We searched medical databases to identify appropriate studies that assessed the impact of NAC on immediate breast reconstruction from the inception of this technique through April 2013. We then performed a meta-analysis of these studies.

Results: Our searches identified 11 studies among 1,840 citations. In the meta-analysis, NAC did not increase the overall rate of complications after immediate breast reconstruction (odds ratio [OR] = 0.59; 95% confidence interval [CI] = 0.38–0.91). The complication rate was also unaffected by NAC when we considered infections (OR = 0.82; 95% CI = 0.46–1.45), hematomas (OR = 1.35; 95% CI = 0.57–3.21), and seromas (OR = 0.77; 95% CI = 0.23–2.55). Additionally, expander or implant loss did not significantly increase in patients after NAC (OR = 1.59; 95% CI = 0.91–2.79). Only 2 studies (202 procedures) had reported total autologous flap loss, and they were included in our analysis; both studies found no association between NAC and total flap loss.

Conclusion: Our analysis suggests that NAC does not increase the complication rate after immediate breast reconstruction. For appropriately selected patients, immediate breast reconstruction following NAC is a safe procedure. The best way to study this issue in the future is to conduct a multicenter prospective study with a longer follow-up period and more clearly defined parameters.

Introduction

Breast conservation surgery, which has become popular in recent years, provides effective locoregional management and improved quality of life when compared with a mastectomy [1]. However, many patients still require mastectomies as standard treatment for breast cancer. Many of these patients choose to undergo immediate breast reconstruction [2]. Breast reconstruction is playing an increasingly significant role in the treatment of breast cancer. There are 3 main types of reconstruction performed on these patients. Patients may undergo autogenous reconstruction, which uses the autogenous tissue alone to perform reconstruction; expander/implant (E/I) reconstruction, which uses expanders or implants to replace the removed breast tissue; or a third approach, which uses both autogenous tissue and E/I for reconstruction. Breast reconstruction can be performed immediately or after the patient recovers from breast cancer surgery, which is called delayed breast reconstruction. Patients who receive immediate reconstruction have better aesthetic results, better psychosocial outcomes, and lower costs of surgery compared to patients who undergo delayed reconstruction or no reconstruction [3]. Furthermore, many studies have shown that immediate breast reconstruction does not increase local or distant recurrence, demonstrating the oncological safety of this technique [4–7]. Immediate breast reconstruction after mastectomy is now routinely recommended for appropriate patients according to the National Comprehensive Cancer Network guidelines [8].

Neoadjuvant chemotherapy (NAC) is defined as adjuvant systemic therapy that is administered prior to, rather than following, locoregional treatment. NAC was first introduced for the management of breast cancer approximately 30 years ago [9,10]. From the time of its introduction, NAC has not only been administered to patients with later-stage cancer to downstage their disease but has also been administered to patients to increase the feasibility of breast conserving surgery; it has also been used to examine the response of the tumor to the chemotherapy regimen [11,12]. However, as nearly all NAC agents are cytotoxic, they may theoretically affect surgical outcomes by causing complications such as infections and problems with wound healing. We wanted...
Table 1. Demographic characteristics and quality scores of studies included in the analysis.

| Author               | Years of diagnosis | Country | Patients (NAC/Control) | Age (range; years) | NAC regimens | Follow-up | Reconstruction type | Outcomes reported                                                                 | NOS score |
|----------------------|--------------------|---------|------------------------|--------------------|--------------|-----------|--------------------|----------------------------------------------------------------------------------|-----------|
| Donker, 2011         | 2006–2009          | Netherlands | 48/215                 | NAC: median 38 (20–62); Control: median 47 (25–70) | AC; Capecitabine+T | 6 weeks   | E/I                | Seroma, hematoma, infection, skin necrosis, surgical re-intervention, implant loss | 8         |
| Jiménez-Puente, 2011 | 2002–2009          | Spain   | 13/102                 | NA                 | FEC; AC-T    | 9 months  | E/I                | Infection, seroma, dehiscence, hemorrhage, mechanical complication, extrusion, necrosis | 6         |
| Radovanovic, 2010    | 2004–2008          | Serbia  | 42/172                 | mean 47 (26–69)    | NA           | 6 weeks   | E/I                | Epidermolysis, infection, skin necrosis, seroma formation, hematoma                | 6         |
| Schaverien, 2013     | 2006–2012          | UK      | 57/65                  | NAC: mean 46.5 (35–54); Control: mean 49 (33–70) | AC-T         | 8–35 months | Auto               | Complete flap loss, hematoma, seroma, infection, donor site breakdown, fat necrosis, mastectomy skin flap necrosis, hospital-acquired pneumonia | 7         |
| Azzawi, 2010         | 2000–2007          | UK      | 58/140                 | NAC: mean 47.8 (29–68); Control: mean 50.4 (29–69) | EC-T; CMF-E; CMF; AT; AC | 7–64 months | E/I, Auto           | Wound infection, slow healing, wound breakdown, fat necrosis, flap loss, partial flap necrosis, hematoma, infected implant, pulmonary embolism | 8         |
| Zweifel-Schlatter, 2010 | 2007–2009         | UK      | 49/58                  | NAC: median 47 (31–68); Control: mean 49 (35–63) | FEC; AC-T    | 30 days   | Auto               | Total or partial flap loss, hematoma, infection, wound healing problem, wound breakdown, seroma | 7         |
| Liu, 2009            | 2001–2007          | Japan   | 12/63                  | NAC: mean 45.3 (26–63); Control: mean 48.3 (30–57) | EC; FEC; T   | NA        | E/I                | Flap necrosis, infection, seroma, hematoma                                       | 7         |
| Godfrey, 1995        | NA                 | USA     | 11/10                  | NA                 | >8 months    | Auto      | Seroma, lymphocele, mastectomy flap slough, cellulitis | 5         |
| Decker, 2012         | 2005–2010          | USA     | 380/8474               | NAC: mean 52.1 ± 12.0; Control: mean 59.63 ± 13.1 | NA           | 30 days   | NA                | Wound complications (superficial surgical site infection, deep infection, wound dehiscence) | 6         |
| Hu, 2011             | 1997–2007          | USA     | 42/214                 | NA                 | AC; TAC; T   | 60 days   | E/I, Auto           | Seroma, hematoma, surgical site infection, dehiscence, open wound, skin necrosis, flap loss | 6         |
| Peled, 2010          | 2005–2007          | USA     | 57/65                  | NAC: mean 46.4 (28–71); Control: mean 49.8 (25–70) | NA           | 8–35 months | E/I, Auto           | Infection, skin flap necrosis, flap loss, E/I loss, unplanned return to the operating room, donor-site complications | 7         |

Abbreviations: Auto, autologous; E/I, expander/implant; NA, not available; NAC, neoadjuvant chemotherapy; NOS, Newcastle-Ottawa Scale. NAC regimens: A, doxorubicin; C, cyclophosphamide; E, epirubicin; F, fluorouracil; M, methotrexate; T, taxotere.

doi:10.1371/journal.pone.0098225.t001
to discern whether NAC increases the rate of complications after immediate breast reconstruction. To address this issue, we performed a meta-analysis to integrate the results from recent studies that have examined the influence of NAC on immediate breast reconstruction after mastectomies.

**Methods**

**Data Sources**

We searched the literature by using PubMed, EMBASE, Google Scholar, the Cochrane Library, the China National Knowledge Infrastructure whole article database, and the VIP Chinese Journals Database to identify studies about the influence of NAC on immediate breast reconstruction after mastectomies. The following terms were used when searching for articles: “preoperative chemotherapy,” “neoadjuvant chemotherapy,” “breast reconstruction,” “outcomes,” and “complications.” We also manually searched the available journals in our library. Unpublished studies were not included in our analysis. No language restrictions were applied to the search. The most recent search was performed on April 1, 2013. The 2 authors (Song and Li) independently examined the titles and abstracts of citations, and they obtained the full text of potentially eligible trials. Disagreements between the authors were resolved by discussion. If a patient cohort was reported more than once, the most informative and recent study with complete data was chosen.

**Inclusion Criteria**

To be included in our analysis, studies had to meet the following criteria: study patients who underwent immediate breast reconstruction after mastectomies to remove breast cancer; the study had to include intervention with preoperative chemotherapy and a control group, report at least 1 outcome mentioned in the Definitions section of this paper, and have a sufficiently long follow-up period (for example, 30 days). Studies could be designed as randomized control trials (RCTs) or a non-RCT.

**Exclusion Criteria**

Studies were excluded from our analysis if they did not include a control group, did not have extractable data, or were case reports or reviews.

**Definitions**

Flap loss was defined as a total loss of circulation in the autologous flap. An infection was defined as localized or systemic evidence of infection that led to administration of oral antibiotics or hospital admission for intravenous antibiotics. A hematoma was defined as a collection of blood at the surgical area that required surgical treatment. A seroma was defined as a clinically obvious collection of serous fluid at the surgical area that required aspiration.

**Quality Score**

We used the Newcastle-Ottawa Scale (NOS) [13,14] to assess the quality of the studies included in our analysis, because the studies were all non-randomized. The 2 authors (Song and Li) independently assessed the included studies and disagreements were resolved by discussion.

**Data Extraction**

The following information was extracted from each eligible trial: authors’ names, country, date, number of patients, method of

---

**Table 2. Raw data showing the complications.**

| Author                      | Reconstruction type | Patients | Total complications | Hematomas | Seromas | Infections | Flap loss | Reoperations |
|-----------------------------|---------------------|----------|---------------------|-----------|---------|------------|-----------|-------------|
| Donker, 2011                | Expander/implant    | 48/215   | 13/102              | 4/42      | 6/215   | 1/48       | 4/48      | 29/215      |
| Jimenez-Puente, 2011        | Expander/implant    | 62/215   | 4/42                | 31/172    | NA      | 11/215     | 62/215    | 55/215      |
| Radovanovic, 2010           | Expander/implant    | 62/215   | 0/48                | 11/215    | NA      | 4/48       | 0/48      | 29/215      |
| Schaverien, 2010            | Expander/implant    | 7/13     | NA                  | NA        | NA      | 4/48       | 7/13      | 19/102      |
| Azzawi, 2010                | Expander/implant    | 58/140   | NA                  | 0/58      | 1/140   | 1/31       | 58/140    | 13/1040     |
| Godfrey, 1995               | Expander/implant    | 11/10    | 2/11                | 0/11      | 1/11    | NA         | 11/10     | 1/110       |
| Liu, 2009                   | Expander/implant    | 42/214   | 15/214              | 2/214     | 1/214   | 1/214      | 5/214     | 2/214       |
| Zweifel-Schlatter, 2010      | Autologous          | 42/214   | 15/214              | 2/214     | 1/214   | 1/214      | 5/214     | 2/214       |
| Peled, 2010                 | Autologous          | 57/65    | NA                  | NA        | NA      | NA         | 57/65     | 57/65       |

Abbreviations: Auto, autologous; E/I, expander/implant; NA, not available; NAC, neoadjuvant chemotherapy.
reconstruction, NAC regimen, and follow-up period (see Tables 1, 2).

Statistical Analysis

Our meta-analysis was performed according to the recommenda-
tions of the Cochrane Collaboration, the Quality of Reporting of Meta-Analyses guidelines, and the Meta-analysis of Observa-
tional Studies in Epidemiology recommendations [15,16]. If the

heterogeneity was not obvious, the odds ratios (ORs) of
postoperative complications were pooled by using a fixed effects
model. Otherwise, we used a random effects model to pool the
ORs. We also conducted a sensitivity analysis to examine the
stability of the pooled results. The heterogeneity between ORs was
assessed by using the I2 index and by performing a test to
determine the overall effect (Z-statistic with P-value). The 95% CI
of all ORs were calculated, and P<0.05 was considered
statistically significant. Analyses were conducted by using Review
Manager version 5.1 (The Cochrane Collaboration, Copenhagen, Denmark). All statistical tests were 2-tailed.

Results

Eligible Studies

Figure 1 illustrates the process of evaluating articles for inclusion in the review and meta-analysis. We obtained 1,840 citations from the previously mentioned databases. We examined the titles and abstracts of these references and excluded all the studies that were clearly ineligible for the analysis. For the remaining articles, we obtained full text copies for further evaluation. In the databases that we searched, we obtained 14 potentially eligible studies that examined the influence of NAC on immediate breast reconstruction [9,11,17–28]. Eleven eligible studies addressed the influence of NAC on immediate breast reconstruction, and these studies also included extractable data; they were included in the review and meta-analysis [9,11,17–23,25,28].

Table 1 summarizes the descriptive data for each of the studies included in this systematic review and meta-analysis. The majority of the studies were performed in the United States and United Kingdom. Most studies were published within the last 10 years. There was only 1 older study, a report by Godfrey et al. [25] published in 1995. Sample sizes ranged from 21 patients to 8,854 patients. On the basis of the methodology and reported data, the studies included in the meta-analysis were deemed to be of a moderate to high quality overall, with all of the included studies ranking ≥3 stars on the modified NOS. Ten of the studies were performed by using medical records to ascertain complications in clinic-based cohorts. One study [17] was performed by using data from the American College of Surgeons National Surgical Quality Improvement Program. Seven studies focused on NAC as the primary exposure, while the other 4 studies evaluated NAC along with several different prognostic factors. These differences in study design and outcome assessment likely produced the heterogeneity identified by performing the Cochran Q and I² statistical analysis.

NAC and Overall Complications

Of the 11 studies in the meta-analysis, 5 reported a risk estimate of NAC with respect to the overall complications. The characteristics and demographics of the selected studies, along with an estimate of precision and list of satisfied eligibility criteria for the meta-analysis, are listed in Table 1. Five studies (n = 829 patients) [9,11,19,20,25] reported the overall complication rate. Although the 5 studies showed no statistical significance individually, the pooled OR was statistically significant. When we pooled the results of these studies, NAC was associated with a decreased risk of overall complications (OR = 0.59; 95% confidence interval [CI] = 0.38–0.91; Fig. 2). In the fixed effect model, the pooled risk estimate for E/I-based reconstruction studies resulted in an OR of 0.49 (95% CI = 0.26–0.89). For studies with larger sample sizes and higher quality, the pooled OR was 0.62 (95% CI = 0.38–0.99). For studies with a short follow-up period (<6 weeks), the pooled OR was 0.44 (95% CI = 0.23–0.87). Exclusion of the study by Donker et al. resulted in the highest pooled estimate (OR = 0.67; 95% CI = 0.40–1.12), and exclusion of the study by Hu et al. resulted in the lowest pooled estimate (OR = 0.44; 95% CI = 0.25–0.79).

![Figure 3. Pooled results of hematomas in patients treated with NAC.](doi:10.1371/journal.pone.0098225.g003)

![Figure 4. Pooled results of seromas in patients treated with NAC.](doi:10.1371/journal.pone.0098225.g004)
The studies included in this review reported different wound complications such as fat necrosis, wound dehiscence, hematoma, and infection. Azzawi et al. [22] demonstrated that minor complications (wound infection, slow healing, wound breakdown, and clinical fat necrosis) and major complications (flap loss, partial flap necrosis, hematoma, implant infection, wound breakdown, and pulmonary embolism) occurred at similar rates in patients who received NAC and those who did not (minor complications: 10% vs. 6%, respectively, P = 0.38; major complications: 9% vs. 9%, respectively, P = 1.0). Hematomas, seromas, and infections were reported in most studies; none of the studies revealed an association between NAC and the occurrence of hematomas, seromas, or infections after surgery. However, a study by Decker et al. [17] did reveal a trend toward increased wound complications in patients who received NAC and underwent mastectomies with immediate reconstruction, although it was not statistically significant (OR = 1.58; 95% CI = 0.98–2.58). For the 5 studies (n = 765 patients) that reported the influence of NAC on the occurrence of hematomas after surgery [9,11,21–23], the pooled result showed that there was no statistically significant difference in the incidence of hematomas between the 2 groups (OR = 1.35; 95% CI = 0.57–3.21; Fig. 3). Similarly, whether or not the patients received NAC did not affect the incidence of seromas (OR = 0.77; 95% CI = 0.23–2.55; Fig. 4) and infections (OR = 0.82; 95% CI = 0.46–1.45; Fig. 5) after immediate breast reconstruction. Three studies that examined the impact of NAC on the reoperation rate presented consistent results; all 3 studies demonstrated that NAC did not increase the reoperation rate.

### NAC and Wound Complications

The studies included in this review reported different wound complications such as fat necrosis, wound dehiscence, hematoma, and infection. Azzawi et al. [22] demonstrated that minor complications (wound infection, slow healing, wound breakdown, and clinical fat necrosis) and major complications (flap loss, partial flap necrosis, hematoma, implant infection, wound breakdown, and pulmonary embolism) occurred at similar rates in patients who received NAC and those who did not (minor complications: 10% vs. 6%, respectively, P = 0.38; major complications: 9% vs. 9%, respectively, P = 1.0). Hematomas, seromas, and infections were reported in most studies; none of the studies revealed an association between NAC and the occurrence of hematomas, seromas, or infections after surgery. However, a study by Decker et al. [17] did reveal a trend toward increased wound complications in patients who received NAC and underwent mastectomies with immediate reconstruction, although it was not statistically significant (OR = 1.58; 95% CI = 0.98–2.58). For the 5 studies (n = 765 patients) that reported the influence of NAC on the occurrence of hematomas after surgery [9,11,21–23], the pooled result showed that there was no statistically significant difference in the incidence of hematomas between the 2 groups (OR = 1.35; 95% CI = 0.57–3.21; Fig. 3). Similarly, whether or not the patients received NAC did not affect the incidence of seromas (OR = 0.77; 95% CI = 0.23–2.55; Fig. 4) and infections (OR = 0.82; 95% CI = 0.46–1.45; Fig. 5) after immediate breast reconstruction. Three studies that examined the impact of NAC on the reoperation rate presented consistent results; all 3 studies demonstrated that NAC did not increase the reoperation rate.

### NAC and Reconstruction Outcomes

Of the included reports, 6 studies [9,18,20,21,23,28] described reconstruction outcomes including E/I loss during E/I reconstruction and total flap loss during autologous reconstruction. For E/I loss, 4 studies [9,18,20,21] provided mixed results. Three studies [9,20,21] revealed no NAC-related increase in the risk of E/I loss in women who underwent E/I reconstruction. However, Jiménez-Puente et al. [18] observed a markedly elevated E/I loss rate (OR = 5.10, P = 0.004) in women who received NAC (7/13 patients with E/I loss) compared to women who did not receive NAC (19/102 patients). The results of our pooled meta-analysis found that NAC was not associated with increased E/I loss (OR = 1.59; 95% CI = 0.91–2.79; Fig. 7). Exclusion of the study by Jiménez-Puente et al. [18], which had a lower quality score than the other studies, led to the lowest pooled OR (OR = 1.15; 95% CI = 0.59–2.24), and exclusion of the study by Donker et al. [9] resulted in the highest estimate (OR = 2.22; 95% CI: 1.12–4.40). Two studies [23,28] that reported the impact of NAC on total flap loss provided consistent results; both studies demonstrated that NAC did not lead to an increase in the incidence of total flap loss after autologous reconstruction.

### NAC and Start of Adjuvant Therapy

Three studies [22,23,28] provided information about whether NAC delayed adjuvant therapy after immediate breast reconstruction. Azzawi et al. [22] reported the interval between breast reconstruction and adjuvant radiotherapy for 67 patients (39

| Study or Subgroup | NAC Events | Total | Control Events | Total | Weight | Odds Ratio M-H, Fixed, 95% CI | Odds Ratio M-H, Fixed, 95% CI |
|-------------------|------------|-------|----------------|-------|--------|-----------------------------|-----------------------------|
| Azzawi et al.2010 | 5          | 58    | 13             | 140   | 19.2%  | 0.92 [0.31, 2.71]            |                             |
| Donker et al.2010 | 6          | 48    | 55             | 215   | 48.4%  | 0.42 [0.17, 1.03]            |                             |
| Peled et al.2010  | 17         | 57    | 18             | 65    | 32.5%  | 1.11 [0.51, 2.43]            |                             |
| Total (95% CI)    | 163        | 420   | 100.0%         |       |        | 0.74 [0.44, 1.22]            |                             |

| Total events | 28 | 86 |
| Heterogeneity: Chi² = 2.73, df = 2 (P = 0.26); I² = 27% |
| Test for overall effect: Z = 1.18 (P = 0.24) |

**Figure 5. Pooled results of infections in patients treated with NAC.** The size of the solid squares is inversely proportional to the variance of the study estimate. The diamond represents the fixed effects odds ratio and 95% confidence interval. doi:10.1371/journal.pone.0098225.g005

**Figure 6. Pooled results of reoperations in patients treated with NAC.** The size of the solid squares is inversely proportional to the variance of the study estimate. The diamond represents the fixed effects odds ratio and 95% confidence interval. doi:10.1371/journal.pone.0098225.g006
treated with NAC and 28 not treated with NAC). The fraction of patients with a delayed adjuvant therapy start time did not significantly differ between the 2 groups (4/39 NAC-treated patients vs. 3/28 control patients; P = 1.00). A prospective study by Zweifel-Schlatter et al. [23] also reached a similar conclusion. However, these were small, single-center studies; therefore, the results are somewhat unconvincing. Future large, multicenter studies are needed to study this issue.

Publication Bias

Figure 8 shows that the plots are relatively symmetric, which means that there is no significant publication bias in the reports of the overall complications. However, because of the limited number of included studies included in the analysis, publication bias might be inevitable.

Discussion

This is the first meta-analysis to examine the impact of NAC on immediate breast reconstruction. Our meta-analysis demonstrated that patients treated with NAC were less likely to suffer negative outcomes such as wound complications (hematomas, seromas, and infections) and reconstruction failure (E/I loss) after immediate breast reconstruction when compared with patients who did not receive NAC. The meta-analysis estimates were robust across sensitivity analyses that accounted for reconstruction type, follow-up period, and study quality.

NAC can kill proliferative cells, and it is known to have adverse effects on the immune system, which might cause a higher complication rate after surgery. We unexpectedly uncovered the interesting phenomenon that patients who received NAC actually had lower complication rates after breast reconstruction. Notably, a meta-analysis of the impact of NAC on breast surgery performed by Mieog et al. [12] reached a similar conclusion. However, it is unclear why improved
outcomes were observed in patients who received NAC. Patient selection bias might have contributed to this phenomenon. In certain studies, the patients in the NAC-treated group who were selected for immediate breast reconstruction were younger and had fewer comorbidities than patients in the control group. The experience and operation skills of the surgeon are also very important factors that could influence early surgical complications. Therefore, it is inappropriate to conclude that NAC can reduce complication rates. However, we can say that patients treated with NAC who are selected by their surgeons as good candidates for immediate breast reconstruction can be expected to have good postoperative outcomes.

Our pooled estimates of the occurrence rates of hematomas, seromas, and infections did not indicate an association between NAC and an increased rate of wound complications, although most of the included individual studies did see an association. We also identified 2 studies that described slightly different results. Decker et al. [17] found a trend toward increased complications in patients treated with NAC who underwent mastectomies with immediate reconstruction, although the trend was not statistically significant (OR = 1.58; 95% CI = 0.98–2.58). In their study, they considered superficial surgical site infections, deep infections, and wound dehiscence to be wound complications, which was different from our criteria for complications. Additionally, their data from axillary dissection and radiotherapy was unclear. They also limited their follow-up time to 30 days, which was shorter than that of some of the other included studies, and this might have contributed to the differences. Moreover, Mehrara et al. [24] presented data as a retrospective review of 952 patients undergoing microvascular reconstruction, and they showed that patients treated with chemotherapy prior to immediate breast reconstruction had a significantly higher incidence of fat necrosis complications. They also did not find any association between NAC and flap loss, partial flap loss, or microvascular complications. This phenomenon might be explained by the complexity of microvascular breast reconstruction, as fat necrosis was more common in this procedure. Although our study findings suggest that NAC is not associated with wound complications after immediate breast reconstruction, it is premature to reach this conclusion. Therefore, further research is needed on this topic.

The pooled estimates in our analysis demonstrated that the E/I loss rate did not increase in patients who received NAC. However, when we performed a sensitivity analysis, we found that the OR became statistically significant if the study by Donker et al. [9] was excluded. The study by Donker et al. was determined to be of high quality; therefore, this result was not very convincing. Therefore, it seems likely that NAC did not increase the E/I loss rates. However, the sample size was small; therefore, we recommend future studies on this issue. Only 2 studies provided data about autologous reconstruction, and both studies did not find any association between NAC and total flap loss. However, it was not possible to reach a firm conclusion. Further studies need to be performed to clarify this issue.

The guiding goal of immediate breast reconstruction is to provide better aesthetic results and improved quality of life. From the time immediate breast reconstruction was first introduced as part of breast cancer treatment, this procedure has gained popularity, and it has been shown to improve quality of life. Many studies have supported the oncological and surgical safety of this procedure [4–6]. Some surgeons hold a conservative attitude toward immediate breast reconstruction in patients treated with NAC. Our analysis supported the conclusion that patients treated with NAC can be expected to have good postoperative outcomes after undergoing immediate breast reconstruction. This finding suggests that patients receiving NAC who are selected by their doctors as good candidates can safely undergo immediate breast reconstruction. However, NAC should not be the only factor considered when determining whether a patient is a good candidate for immediate breast reconstruction; other factors including age, body mass index (BMI), and diabetes mellitus are also risk factors that might lead to higher complication rates and even failure of reconstruction. Jiménez-Puente et al. [18] analyzed 118 patients who underwent immediate breast reconstruction after mastectomies, and they found that the age of the patients was related to the risk of reconstruction failure (OR = 3.02, P = 0.02). Decker et al. [17] performed a logistic analysis of 44,533 breast surgeries by using a multivariable model to explore factors associated with wound complications. They found that smoking, obesity, and diabetes mellitus were predictive factors of wound complications after breast surgery (smoking: OR = 1.56, P < 0.0001; obesity: OR = 2.16, P < 0.0001; diabetes mellitus: OR = 1.57, P < 0.0001). Therefore, consideration of variables other than NAC treatment is very important when determining whether patients should undergo immediate breast reconstruction.

Certain limitations were inevitable in this analysis. First, we did not consider certain confounding factors (such as BMI and age), the different NAC regimens used, and the interval between NAC and surgery, because the original data for all these was unavailable. These factors might affect the rate of complications after reconstruction. Second, selection bias, especially the tendency to administer NAC to patients with later-stage tumors, was a particular problem in most of the studies. Third, differences in the follow-up periods may also limit interpretation of the results. Lastly, all the studies in our analysis were non-RCTs, the results of which are not as convincing as those of RCTs. All these limitations might affect, to a certain extent, the validity of our conclusions.

Conclusions

This meta-analysis suggests that NAC does not increase the complication rate after immediate breast reconstruction. Immediate breast reconstruction following NAC treatment was a safe procedure for appropriately selected patients. However, the majority of studies were performed via retrospective analysis to examine small numbers of patients at single centers. Therefore, we believe that a multicenter prospective study with a longer follow-up period and more clearly defined parameters would be the best way to study this issue in the future.

Supporting Information

Checklist S1  PRISMA Checklist. (DOC)

Author Contributions

Conceived and designed the experiments: JLS XZ H.Li. Analyzed the data: XJL YYS H.Liu. Wrote the paper: JLS H.Li.
References

1. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M et al. (2002) Twenty-year follow up of a randomized trial comparing total mastectomy, lumpectomy and lumpectomy plus radiation for the treatment of invasive breast cancer. N Engl J Med 347: 1233–1241.

2. Chevray PM. (2008) Timing of breast reconstruction: immediate versus delayed. Cancer J 14(4): 223–229.

3. Al-Ghazal SK, Sully L, Fallossfield L, Blamey RW et al. (2000) The psychological impact of immediate rather than delayed breast reconstruction. Eur J Surg Oncol Feb; 26(1): 9–17.

4. Langstein HN, Cheng MH, Singletary SE, Robb GL, Hoy E et al. (2003) Breast cancer recurrence after immediate reconstruction: Patterns and significance. Plast Reconstr Surg 111: 712–720; discussion 721–722.

5. Mustonen P, Lepisto A, Papp A, Berg M, Pietilainen T et al. (2004) The surgical and oncological safety of immediate breast reconstruction. Eur J Surg Oncol 30: 817–823.

6. Taylor CW, Horgan K, Dodwell D. (2005) Oncological aspects of breast reconstruction. The Breast 14: 118–130.

7. Gouy S, Rouzier R, Missana MC, Atallah D, Atallah D et al. (2005) Immediate surgical complications of skin sparing mastectomy and immediate prosthetic reconstruction after NAC for invasive breast cancer. Eur J Surg Oncol 38: 25–30.

8. Chevray PM. (2008) Timing of breast reconstruction: immediate versus delayed. Cancer J 14(4): 223–229.

9. NCCN.org. (2012) NCCN clinical practice guidelines in oncology: breast cancer; Version 1.

10. Mustonen P, Lepisto A, Papp A, Berg M, Pietilainen T et al. (2004) The surgical and oncological safety of immediate breast reconstruction. Eur J Surg Oncol 30: 817–823.

11. Lui Y, Mori H, Hata Y. (2009) Does neoadjuvant chemotherapy for breast cancer increase complications during immediate breast reconstruction? J Med Dent Sci Mar; 56(1): 55–60.

12. NCCN.org. (2012) NCCN clinical practice guidelines in oncology: breast cancer; Version 1.

13. Taggart DP, D’Amico R, Altman DG. (2001) Effect of arterial revascularisation on survival: a systematic review of studies comparing bilateral and single internal mammary arteries. Lancet 358: 870–875.

14. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD et al. (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 283: 2008–2012.

15. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D et al. (1999) Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 354(9193): 1896–900.

16. Decker MR, Greenblatt DY, Havlena J, Wilke LG, Greenberg CC et al. (2012) Impact of neoadjuvant chemotherapy on wound complications after breast surgery. Surgery 152: 382–389.

17. Al-Ghazal SK, Sully L, Fallossfield L, Blamey RW et al. (2000) The psychological impact of immediate rather than delayed breast reconstruction. Eur J Surg Oncol Feb; 26(1): 9–17.

18. Taggart DP, D’Amico R, Altman DG. (2001) Effect of arterial revascularisation on survival: a systematic review of studies comparing bilateral and single internal mammary arteries. Lancet 358: 870–875.

19. Godfrey PM, Godfrey NV, Ronnita MC. (1995) Immediate autogenous breast reconstruction in clinically advanced disease. Plast Reconstr Surg 95: 1039–1042.

20. Godfrey PM, Godfrey NV, Ronnita MC. (1995) Immediate autogenous breast reconstruction in clinically advanced disease. Plast Reconstr Surg 95: 1039–1042.

21. Hu YY, Weeks CM, In H, Hodgson CM, Golshan M et al. (2011) Impact of neoadjuvant chemotherapy on breast reconstruction. Cancer 117: 2833–41.

22. Azzawi K, Ismail A, Earl H, Forouhi P, Malata CM et al. (2010) Influence of neoadjuvant chemotherapy on outcomes of immediate breast reconstruction. Plast Reconstr Surg 126: 1.

23. Zweifel-Schlatter M, Darhouse N, Roblin P, Ross D, Zweifel M et al. (2010) Immediate microvascular breast reconstruction after neoadjuvant chemotherapy: complication rates and effect on start of adjuvant treatment. Ann Surg Oncol 17: 2945–2950.

24. Mehrara BJ, Santoro TD, Atrilla E, Watson JP, Shaw WW et al. (2006) Complications after microvascular breast reconstruction: experience with 1195 flaps. Plast Reconstr Surg 118: 1100–1109; discussion: 1110–1111.

25. Godfrey PM, Godfrey NV, Ronnita MC. (1995) Immediate autogenous breast reconstruction in clinically advanced disease. Plast Reconstr Surg 95: 1039–1044.

26. Godfrey PM, Godfrey NV, Ronnita MC. (1995) Immediate autogenous breast reconstruction in clinically advanced disease. Plast Reconstr Surg 95: 1039–1044.

27. Godfrey PM, Godfrey NV, Ronnita MC. (1995) Immediate autogenous breast reconstruction in clinically advanced disease. Plast Reconstr Surg 95: 1039–1044.

28. Godfrey PM, Godfrey NV, Ronnita MC. (1995) Immediate autogenous breast reconstruction in clinically advanced disease. Plast Reconstr Surg 95: 1039–1044.